Looby M, Linke R, Weiss M
Department of Pharmacology, Martin Luther University Halle-Wittenberg, Halle, Germany.
Cancer Chemother Pharmacol. 1997;39(6):554-6. doi: 10.1007/s002800050614.
A three-compartment model was fitted to idarubicin data in a NONMEM pooled-data approach. Clearance (CL) of 221.7 ml/min was relatively high, and drug distribution was rapid (CLD = 248.3 ml/min) and extensive [steady-state volume of distribution (Vss) 24 1]. The area under the concentration-time curve (AUC) of idarbicinol was 8 times that of idarubicin. Concentrations of idarubicin (idarubicinol) measured in the myocardium at 24 h after i.v. administration of idarubicin were 20 (5) times those determined in plasma. Tissue concentrations of idarubicinol were up to 400 times those of idarubicin, indicating that the active metabolite contributes significantly to the overall drug action.
采用NONMEM合并数据方法,将三室模型拟合至伊达比星数据。清除率(CL)为221.7 ml/分钟,相对较高,药物分布迅速(CLD = 248.3 ml/分钟)且广泛[稳态分布容积(Vss)为24 1]。伊达比星醇的浓度-时间曲线下面积(AUC)是伊达比星的8倍。静脉注射伊达比星后24小时,心肌中测得的伊达比星(伊达比星醇)浓度是血浆中浓度的20(5)倍。伊达比星醇的组织浓度高达伊达比星的400倍,表明活性代谢产物对总体药物作用有显著贡献。